Stock Buybacks (Quarterly) Chart

View Stock Buybacks (Quarterly) for GERN.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Stock Buybacks (Quarterly) Chart
Start Trial

Historical Stock Buybacks (Quarterly) Data

View and export this data back to 1998. Start Trial.
Date Value
June 30, 2026 -1.384M
March 31, 2026 -2.425M
December 31, 2025 -0.378M
September 30, 2025 -0.542M
June 30, 2025 -1.091M
March 31, 2025 -0.256M
December 31, 2024 -6.597M
September 30, 2024 -3.578M
June 30, 2024 -16.83M
March 31, 2024 -147.80M
December 31, 2023 -3.58M
September 30, 2023 -29.35M
June 30, 2023 -18.34M
March 31, 2023 -281.05M
December 31, 2022 -11.75M
September 30, 2022 -4.839M
June 30, 2022 -70.68M
March 31, 2022 0.00
December 31, 2021 -4.744M
September 30, 2021 0.00
June 30, 2021 -2.654M
March 31, 2021 -16.26M
December 31, 2020 -0.111M
September 30, 2020 0.579M
June 30, 2020 -144.26M
Date Value
March 31, 2020 -0.686M
December 31, 2019 -10.27M
September 30, 2019 -8.984M
June 30, 2019 -0.243M
March 31, 2019 0.00
December 31, 2018 -0.008M
September 30, 2018 -9.087M
June 30, 2018 -82.32M
March 31, 2018 -1.553M
December 31, 2017 -1.074M
September 30, 2017 0.00
June 30, 2017 -0.037M
March 31, 2017 0.00
December 31, 2016 -0.012M
September 30, 2016 -0.09M
June 30, 2016 -0.241M
March 31, 2016 -0.826M
December 31, 2015 -0.81M
September 30, 2015 -0.21M
June 30, 2015 -0.078M
March 31, 2015 -1.477M
December 31, 2014 -0.53M
September 30, 2014 -0.105M
June 30, 2014 -0.105M
March 31, 2014 -97.62M

Stock Buyback Definition

Stock buybacks are when companies buy back their own stock, removing it from the marketplace. Stock buybacks increase the value of the remaining shares because there is now less common stock outstanding and company earnings are split among fewer shares.

Read full definition.

Stock Buybacks (Quarterly) Range, Past 5 Years

View Stock Buybacks (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Stock Buybacks (Quarterly) Benchmarks

View Stock Buybacks (Quarterly) Benchmarks
Start Trial
Precigen, Inc. -1.316M
Editas Medicine, Inc. -117.54M
Agenus, Inc. -14.71M
Amgen, Inc. 0.00
Anika Therapeutics, Inc. 0.643M